Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Medicare drug plans can now cover Eli Lilly's blockbuster obesity drug Zepbound for obstructive sleep apnea, the Centers for Medicare & Medicaid Services confirmed to CNBC. That opens the door for ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Medicare’s $35 insulin price cap was signed into law through the Inflation Reduction Act, which means it would take another ...

Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Medicare’s $35 insulin price cap was signed ... In 2023, insulin manufacturer Eli Lilly voluntarily capped out-of-pocket costs for its insulin at $35 at participating pharmacies for people ...